arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

AGENUS INC

AGEN
$6.43 ▼ -0.57 (-8.14%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
18 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
47
Health
Weak
Neutral
auto_awesome

Analytical Summary

AGENUS INC demonstrates solid fundamentals with strength in Debt to Equity. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $191.2M
Dividend Yield —
Revenue Growth 10.4% ↗
Op. Margin -17.7% ↗
ROIC 8.9% ↘
FCF / Share $-2.60 ↗
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity -0.16
info Valuation on last close. End-of-day price, Nov 5, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$114.20M
↑ +10.4% —
Net Income Profit after all expenses
$-3.08M
↑ +98.7% —
Operating Margin Operating profit as % of sales
-17.7%
↑ +84.8% 11th
FCF / Share Free cash flow per share
$-2.60
↑ +64.9% —
Long-Term Debt Long-term obligations
$44.66M
↑ +34.6% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile

Health Breakdown

Profitability →
14
Returns ↓
46
Financial Health
63
Cash Quality ↑
99

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 18 years · 68 quarters